Literature DB >> 9794425

Proapoptotic activity of a Trypanosoma cruzi ceramide-containing glycolipid turned on in host macrophages by IFN-gamma.

C G Freire-de-Lima1, M P Nunes, S Corte-Real, M P Soares, J O Previato, L Mendonça-Previato, G A DosReis.   

Abstract

The effects of glycoinositolphospholipid (GIPL), from the pathogenic protozoan Trypanosoma cruzi, and its isolated glycan and lipid (dihydroceramide) components, were investigated in J774 cells and primary macrophages. Isolated GIPL ceramide, but not intact GIPL or its glycan, induced intense fluid phase endocytosis when added exogenously. In the presence of the cytokine IFN-gamma, GIPL ceramide induced marked apoptosis in J774 cells and macrophages, independent of nitric oxide secretion. When cells were preincubated with the GIPL-derived glycan chain, addition of intact GIPL induced macrophage apoptosis in the presence of IFN-gamma. Synthetic C2-dihydroceramide also induced apoptosis in the presence of IFN-gamma. Induction of apoptosis in T. cruzi-infected macrophages by GIPL ceramide plus IFN-gamma led to increased parasite release compared with IFN-gamma treatment alone. Viable parasites released comprised both infective trypomastigote and spheromastigote forms. These results identify a novel pathway by which T. cruzi glycosylphosphatidylinositol family molecules affect host macrophages, with implications for the infectious process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794425

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Impaired Kupffer cells in highly susceptible mice infected with Trypanosoma congolense.

Authors:  Meiqing Shi; Guojian Wei; Wanling Pan; Henry Tabel
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Excretory-secretory product of newly excysted metacercariae of Paragonimus westermani directly induces eosinophil apoptosis.

Authors:  M H Shin
Journal:  Korean J Parasitol       Date:  2000-03       Impact factor: 1.341

3.  Modulation of B-lymphocyte and NK cell activities by glycoinositolphospholipid purified from Trypanosoma cruzi.

Authors:  L B De Arruda Hinds; L M Previato; J O Previato; Q Vos; J J Mond; L M Peçanha
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Regulated expression and effect of galectin-1 on Trypanosoma cruzi-infected macrophages: modulation of microbicidal activity and survival.

Authors:  E Zúñiga; A Gruppi; J Hirabayashi; K I Kasai; G A Rabinovich
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Glycoinositolphospholipids from Trypanosoma cruzi induce B cell hyper-responsiveness in vivo.

Authors:  A M Bilate; J O Previato; L Mendonça-Previato; L M Peçanha
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

6.  Trypanosoma cruzi infection and nuclear factor kappa B activation prevent apoptosis in cardiac cells.

Authors:  Christine A Petersen; Katherine A Krumholz; John Carmen; Anthony P Sinai; Barbara A Burleigh
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

7.  Glycoinositolphospholipids from Trypanosoma cruzi interfere with macrophages and dendritic cell responses.

Authors:  Claudia Brodskyn; Julie Patricio; Rubem Oliveira; Lucas Lobo; Andrea Arnholdt; Lucia Mendonça-Previato; Aldina Barral; Manoel Barral-Netto
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Sleeping with the enemy: how intracellular pathogens cope with a macrophage lifestyle.

Authors:  Emily P Thi; Ulrike Lambertz; Neil E Reiner
Journal:  PLoS Pathog       Date:  2012-03-22       Impact factor: 6.823

9.  Regulatory cells and immunosuppressive cytokines: parasite-derived factors induce immune polarization.

Authors:  Ali Ouaissi
Journal:  J Biomed Biotechnol       Date:  2007

Review 10.  Trypanosoma cruzi and its components as exogenous mediators of inflammation recognized through Toll-like receptors.

Authors:  Marco A Campos; Ricardo T Gazzinelli
Journal:  Mediators Inflamm       Date:  2004-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.